Personalized Planning Using CFD-Based Dosimetry for Transarterial Radioembolization in Liver Cancer Patients with Hepatocellular Carcinoma

What this Trial Is About

This research focuses on hepatocellular carcinoma HCC, a primary form of liver cancer, and evaluates a new approach to improve treatment planning for transarterial radioembolization TARE. TARE is a minimally invasive therapy where radioactive microspheres are delivered into the livers blood vessels to target tumors. Despite its use, treatment outcomes vary due to complex liver blood flow and unpredictable microsphere distribution. The goal is to develop a personalized, patient-specific pre-treatment planning platform using computational models to better predict and optimize treatment outcomes. The study involves creating 3D digital models of each patients liver arterial tree based on clinical imaging like CT, MRI, PET, SPECT, or DSA. These models use computational fluid dynamics CFD and radiation dosimetry simulations to study how treatment parameters affect the distribution of microspheres and radiation dose. The clinical part includes collecting retrospective and prospective imaging and treatment data from patients undergoing TARE without altering their treatment, aiming to build and validate these models. Participants provide imaging and treatment data which researchers use to analyze blood flow, microsphere transport, and radiation dose distribution. The study measures the accuracy of the CFD models, identifies key treatment parameters, and quantifies uncertainty in radiation dose to tumors and healthy liver tissue over four years. This data collection involves no additional risk or changes to clinical care, and the insights gained may support future personalized and safer TARE planning. The overall study period extends until the end of 2030.

An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer